Eradivir, Inc.
Eradivir is a biotechnology company focused on developing drugs that guide the immune system to fight disease, including viral infections and cancer. Their innovative platform, BAiT, uses small molecule immunotherapies to target and destroy diseased cells. The company is advancing a lead molecule, EV25, which has shown superior efficacy against influenza in preclinical studies and is currently in Phase I clinical trials. Eradivir aims to develop pharmaceuticals for multiple diseases using their modular platform and is committed to transparency and scientific progress.
Industries
Nr. of Employees
small (1-50)
Products
Influenza-targeted small-molecule bispecific immunotherapy (lead clinical candidate)
A modular small-molecule therapeutic that targets influenza-infected cells and recruits circulating antibodies to trigger innate immune effector cells, demonstrated to reduce viral loads in preclinical models and progressed into early human trials.
Pipeline variants for other respiratory viruses and nonviral indications
Development-stage variants of the modular platform intended to target RSV, other respiratory viruses, and selected nonviral infections using the same ligand-plus-immunologic-payload approach.
Influenza-targeted small-molecule bispecific immunotherapy (lead clinical candidate)
A modular small-molecule therapeutic that targets influenza-infected cells and recruits circulating antibodies to trigger innate immune effector cells, demonstrated to reduce viral loads in preclinical models and progressed into early human trials.
Pipeline variants for other respiratory viruses and nonviral indications
Development-stage variants of the modular platform intended to target RSV, other respiratory viruses, and selected nonviral infections using the same ligand-plus-immunologic-payload approach.
Services
Discovery, lead optimization, in vitro and in vivo efficacy testing, PK/PD and biomarker studies to advance small-molecule immunotherapies from hit to candidate selection.
Design and operational management of early-phase clinical trials, including ICH GCP-compliant conduct, registry reporting, and execution of human challenge studies when applicable.
End-to-end management of drug substance and drug product CMC activities across preclinical and clinical stages, including vendor qualification, process and method validation, stability testing, and supply distribution.
Discovery, lead optimization, in vitro and in vivo efficacy testing, PK/PD and biomarker studies to advance small-molecule immunotherapies from hit to candidate selection.
Design and operational management of early-phase clinical trials, including ICH GCP-compliant conduct, registry reporting, and execution of human challenge studies when applicable.
End-to-end management of drug substance and drug product CMC activities across preclinical and clinical stages, including vendor qualification, process and method validation, stability testing, and supply distribution.
Expertise Areas
- Targeted small-molecule immunotherapy development
- Antiviral drug discovery and preclinical development
- Clinical trial design and execution (Phase 1–2, human challenge studies)
- CMC program management and CDMO coordination
Key Technologies
- Small-molecule bispecific immunotherapies
- Ligand-targeted delivery to infected or diseased cells
- Hapten-mediated antibody recruitment
- Intranasal drug delivery (preclinical and clinical use)
News & Updates
Purdue University News reports that Eradivir is conducting a Phase 2 challenge study following a successful Phase 1 trial where EV25 was well tolerated.
Research published in Proceedings of the National Academy of Sciences shows EV25's superior efficacy in preclinical models.
BBC World Service features an interview discussing how Eradivir's approach could trick immune cells into tackling flu infections.
Funding will support a Phase 2a challenge study of EV25.
Eradivir leverages small molecule targeting technology developed at Purdue University for viral infections.
Academic paper discussing immune cell recruitment for influenza treatment.
Purdue University News reports that Eradivir is conducting a Phase 2 challenge study following a successful Phase 1 trial where EV25 was well tolerated.
Research published in Proceedings of the National Academy of Sciences shows EV25's superior efficacy in preclinical models.
BBC World Service features an interview discussing how Eradivir's approach could trick immune cells into tackling flu infections.
Funding will support a Phase 2a challenge study of EV25.
Eradivir leverages small molecule targeting technology developed at Purdue University for viral infections.
Academic paper discussing immune cell recruitment for influenza treatment.